CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy a ...
Phase 2
Los Angeles, California, United States of America and 2 other locations
(ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast...
Phase 2
Los Angeles, California, United States and 3 other locations
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of C...
Phase 1
Beverly Hills, California, United States and 3 other locations
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a ...
Phase 1, Phase 2
Los Angeles, California, United States and 4 other locations
to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast...
Phase 2
Duarte, California, United States and 10 other locations
in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast...
Phase 1, Phase 2
Los Angeles, California, United States of America and 1 other location
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer...
Phase 1
Santa Monica, California, United States and 8 other locations
This trial will evaluate the use of immunotherapy and PARP inhibition in a population with incurable advanced breast cancer associa ...
Phase 2
Los Angeles, California, United States of America
Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...
Phase 3
Santa Monica, California, United States and 35 other locations
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Rec ...
Phase 2
Los Angeles, California, United States and 14 other locations
Clinical trials
Research sites
Resources
Legal